Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H, Mahmoudjafari Z, Rockey M, Henry D, Grauer D, Aljitawi O, Abhyankar S, Ganguly S, Lin T, McGuirk J. Luu Tran H, et al. Among authors: mahmoudjafari z. J Oncol Pharm Pract. 2016 Apr;22(2):228-34. doi: 10.1177/1078155214560920. Epub 2014 Dec 3. J Oncol Pharm Pract. 2016. PMID: 25471252 Free PMC article.
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, Strouse C, Lochner J, Mahmoudjafari Z, Raza S, Valent J, Anderson LD Jr, Anwer F, Abdallah AO, Hashmi H. Dima D, et al. Among authors: mahmoudjafari z. Transplant Cell Ther. 2024 Mar;30(3):308.e1-308.e13. doi: 10.1016/j.jtct.2023.12.016. Epub 2023 Dec 26. Transplant Cell Ther. 2024. PMID: 38151105
Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone.
Alkharabsheh O, Bellman P, Mahmoudjafari Z, Cui W, Atrash S, Paul B, Hashmi H, Shune L, Ahmed N, Abdallah AO. Alkharabsheh O, et al. Among authors: mahmoudjafari z. J Hematol. 2023 Feb;12(1):1-6. doi: 10.14740/jh1085. Epub 2023 Feb 25. J Hematol. 2023. PMID: 36895290 Free PMC article.
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H, Atrash S, Jain J, Khasawneh G, Mohan M, Mahmoudjafari Z, Cui W, McGuirk J, Shune L, Ahmed N, Abdallah AO. Hashmi H, et al. Among authors: mahmoudjafari z. Transplant Cell Ther. 2023 Apr;29(4):262.e1-262.e6. doi: 10.1016/j.jtct.2023.01.013. Epub 2023 Jan 20. Transplant Cell Ther. 2023. PMID: 36682468 Free article.
Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma.
Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Hajjar S, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah AO. Atieh T, et al. Among authors: mahmoudjafari z. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):912-919. doi: 10.1016/j.clml.2022.08.003. Epub 2022 Aug 15. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36127271
33 results